Press Releases

BETHESDA, Md., December 21, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility. The MHRA license approval enables the... Read More

BETHESDA, Md., November 29, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company’s cash reserves above $20 million. The Company plans to use the funding to help accelerate its activities related to its brain cancer program. The... Read More

BETHESDA, Md., October 28, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company’s manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.... Read More

FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Application Submitted to MHRA for Certification of Sawston Facility BETHESDA, Md., May 12, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing... Read More

FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility Application for MHRA Regulatory Certification of Facility In Preparation BETHESDA, Md., March 16, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax®... Read More